Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced that it has been granted a U.S. Patent, No. 12,350,242, titled "BINGE BEHAVIOR REGULATORS", by the United States Patent and Trademark Office (USPTO).

The patent, which refers to Clearmind's molecule MEAI (5-methoxy-2-aminoindane), covers innovative compositions and methods utilizing a pharmaceutically acceptable salt to regulate binge behaviors, including excessive drinking, eating, and gambling.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.